ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2829

Complete Epigenetic Landscape of Rheumatoid Arthritis Fibroblast-like Synoviocytes Reveals Unanticipated Critical Pathogenic Pathways

Rizi Ai1, Teresina Laragione2, Deepa Hammaker3, David L. Boyle4, Andre ‎ Wildberg5, Keisuke Maeshima3, Emmanuele Palescandolo6, Vinod Krishna6, Bryan Linggi7, David Pocalyko8, John W. Whitaker9, Percio S. Gulko2, Wei Wang10 and Gary S. Firestein11, 1UC San Diego, La Jolla, CA, 2Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 4University of California San Diego, La Jolla, CA, 5Chemistry and Biochemistry, UNIVERSITY OF CALIFORNIA SAN DIEGO, LA JOLLA, CA, 6Janssen Pharmaceuticals, Spring House, PA, 7janssen Pharmaceuticals, Spring House, PA, 8Janssen Research, Spring House, PA, 9Janssen Pharmaceuticals, La Jolla, CA, 10Chemistry and Biochemistry, UC San Diego, La Jolla, CA, 11Medicine, University of California San Diego, La Jolla, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Epigenetics, Fibroblasts, pathogenesis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Genetics, Genomics and Proteomics

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Epigenetics participates in the pathogenesis of rheumatoid arthritis (RA). Epigenetic marks, gene expression and DNA polymorphisms have been investigated but the analyses are limited to few marks and simple combination methods. In the present study, we used a novel algorithm (EpiSeq) to integrate epigenomes for RA FLS in an unbiased fashion combining whole genome histone modifications, open chromatin, RNA expression and DNA methylation. By focusing on the chromatin states of regulatory elements and using a new computational platform, we identified unexpected pathways that contribute to the pathogenesis of RA.

Methods: We applied multiple omics technologies on 11 RA and 11 osteoarthritis [OA] FLS: ChIPseq for histone modifications, ATACseq for open chromatin, RNAseq for transcriptomes and whole genome bisulfite sequencing (WGBS) for DNA methylation. The complex multidimensional relationships were addressed with our novel unbiased method, EpiSig, which is a flexible framework for integrative analysis of any type of sequencing data and identifies epigenomically co-modified regions that share similar patterns. Common epigenetic modification patterns were identified on a global genome scale and the genome was segmented into regulatory/functional elements. The epigenetic state of each element was defined and differentially modified epigenetic regions (DMER) between RA and OA were identified. Pathway evaluation used Ingenuity Pathway Analysis. Bostatistical analyses used Benjamini-Hochberg corrections.

Results: 218 genome-wide datasets were generated across FLS samples, including 152 histone modification datasets (H3K27ac, H3K4me1, H3K4me3, H3K36me3, H3K27me3, H3K9me3), 22 DNA methylation datasets, 22 open chromatin datasets and 22 transcriptome datasets. Eighteen epigenomic states were defined with distinct FLS chromatin signatures, including 4 promoter states, 6 enhancer states, 2 transcribed states, 2 states with zinc finger protein genes and 4 repressed states. The genome was segmented into 5 kb regions, and 125 epigenetic clusters sith similar epigenetic patterns were determined across FLS. We identified regions that were differentially marked when comparing OA and RA. 13 clusters with significant DMER enrichment in RA were identified, which were grouped into biological pathways based on genes associated with these promoters and enhancers. Among the pathways that were significantly different in RA FLS, Phospholipase C Signaling, p53 Signaling, Integrin Signaling, and Protein Kinase A signaling were particularly notable. Other pathways were unexpected, such as Huntington’s Disease Signaling (HDS). To biologically validate the HDS pathway, we showed that one key member of HDS, namely HIP1, is expressed in FLS. HIP1 deficiency induced by siRNA knockdown decreased cultured RA FLS invasion into an artificial matrix by 56% (p<0.001).

Conclusion: We developed the first high-resolution global epigenomic landscape for RA and using a novel method to prioritize RA-specific biological pathways. Biologic validation of one unanticipated target in HDS pathway confirms that this unbiased method can identify novel therapeutic targets.


Disclosure: R. Ai, None; T. Laragione, None; D. Hammaker, None; D. L. Boyle, None; A. Wildberg, None; K. Maeshima, None; E. Palescandolo, Janssen Pharmaceutica Product, L.P., 3; V. Krishna, Janssen RD LLC, 3; B. Linggi, Johnson & Johnson, 3; D. Pocalyko, Johnson & Johnson, 1,Johnson & Johnson, 3; J. W. Whitaker, Johnson & Johnson, 3; P. S. Gulko, None; W. Wang, None; G. S. Firestein, Janssen Pharmaceutica Product, L.P., 2.

To cite this abstract in AMA style:

Ai R, Laragione T, Hammaker D, Boyle DL, Wildberg A, Maeshima K, Palescandolo E, Krishna V, Linggi B, Pocalyko D, Whitaker JW, Gulko PS, Wang W, Firestein GS. Complete Epigenetic Landscape of Rheumatoid Arthritis Fibroblast-like Synoviocytes Reveals Unanticipated Critical Pathogenic Pathways [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/complete-epigenetic-landscape-of-rheumatoid-arthritis-fibroblast-like-synoviocytes-reveals-unanticipated-critical-pathogenic-pathways/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complete-epigenetic-landscape-of-rheumatoid-arthritis-fibroblast-like-synoviocytes-reveals-unanticipated-critical-pathogenic-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology